We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Exhibits Intelligent and Integrated Portfolio of IVD Solutions at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 27 Sep 2021
Print article
Image: Siemens Exhibits Intelligent and Integrated Portfolio of IVD Solutions at AACC Clinical Lab Expo (Photo courtesy of Siemens Healthineers)
Image: Siemens Exhibits Intelligent and Integrated Portfolio of IVD Solutions at AACC Clinical Lab Expo (Photo courtesy of Siemens Healthineers)

Siemens Healthineers (Erlangen, Germany) exhibited its intelligent, integrated range of IVD solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held in Atlanta on September 26-30.

AACC's annual meeting is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries. At this year’s AACC, Siemens highlighted its Atellica Solution range of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The Atellica Solution is comprised of sample management, as well as immunoassay and chemistry analyzers, and is an excellent fit for mid-and high-volume labs. It delivers unprecedented flexibility to adapt to changing testing needs and space constraints. The company demonstrated how its Atellica Integrated Automation (AIA) on the Atellica Solution consolidated revolutionary sample management technology, intelligent software, and IT to provide workflow efficiency with the flexibility to add decapping with little or no additional footprint.

Siemens also demonstrated its new, more-scalable automation solutions that include pre- and post-analytics for labs of all sizes to accommodate their specific needs, testing volumes, and resources. Siemens showed how labs could achieve open, one-touch, end-to-end testing with Aptio Automation; Drive open, one-touch sample preparation for multidisciplinary labs with its Atellica Task Targeted Automation; and streamline lab’s biggest chemistry and immunoassay workloads with the Atellica Integrated Automation

Siemens also introduced its new Atellica Hematology Portfolio that pairs analyzers and automation with intelligence to streamline operations and support accurate clinical decision-making that’s on-time, every time. The company displayed two new flagship hematology analyzers - Atellica HEMA 570 and 580 – that are designed to deliver reliable performance targeted for high volume routine workloads.

Siemens is currently developing the Atellica CI 1900 System for the lower-to-mid-volume laboratories. It is planned to utilize the same menu, reagents, consumables, and detection technology as the Atellica Solution2. The Atellica CI 1900 System1 is being designed to take the lab a step beyond by offering the same workflow and IT across the network with the goal of redefining standardization.

Related Links:
Siemens Healthineers

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more